SCHEMBL2249852

SCHEMBL2249852

COc1cc(-c2nc3ccc(C)cn3c2Nc2ccc3c(c2)OCO3)cc(F)c1O

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 19/20 0.70
▸ GAA P10253 16/20 0.70
▸ KDM4E B2RXH2 5/20 0.70
▸ ALDH1A1 P00352 5/20 0.70
▸ SMN1; SMN2 Q16637 5/20 0.70
▸ HPGD P15428 4/20 0.70
▸ HTT P42858 4/20 0.70
▸ L3MBTL1 Q9Y468 3/20 0.70
▸ TDP1 Q9NUW8 2/20 0.70
▸ LMNA P02545 2/20 0.70
▸ TP53 P04637 7/20 0.64
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ THRB P10828 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ RAB9A P51151 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252119 0.95 MAPT (0.78) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2252757 0.89 MAPT (0.69) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2252295 0.88 MAPT (0.64) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL14022536 0.86 GAA (0.63) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2252820 0.84 GAA (0.69) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL14022630 0.84 GAA (0.76) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2255047 0.83 GAA (0.67) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL10077266 0.82 MAPT (1.00) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2250631 0.82 MAPT (1.00) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL14022507 0.82 GAA (0.55) MAPTGAAKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US claimed
EP-2155747-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS Acadia Pharmaceuticals Inc. (US) 2010-02-24 — — EP claimed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO claimed
EP-2155747-B1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LTD (GB) 2012-10-24 — — EP disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS CNR1, CNR2, GPR18 MAPT 2915/4885GAA 4087/4885KDM4E 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback